Molecular Mechanism of EGFR Signaling Pathway Mediating Proliferation and Migration of U251 Glioma Cell Line

Molecular Mechanism of EGFR Signaling Pathway Mediating Proliferation and Migration of U251 Glioma Cell Line

Loading document ...
Page
of
Loading page ...

Author(s)

Author(s): Linlin YUE, Ling LI, Bin WANG, Xiangmin YU, Lingling DING, Linlin Wang, Yingying Li

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.1148 420 805 61-66 Volume 5 - Nov 2016

Abstract

The EGFR, epidermal growth factor recepor, is a 170 kDa transmembrane glycoprotein and belongs to receptor tyrosine kinases family. Actual evidence shows that overexpression of EGFR is involved in 50% –70% of various diseases. However, there is limited evidence regarding the role of EGFR in the tumorigenesis of human gliomas. In the present study, its effects on U251 cell proliferation and migration were examined using CCK and scratch-wound assay. We found that AG1478 inhibit EGF-induced U251 cells proliferation and migration. Moreover, it was demonstrated that the downregulation of p-EGFR in U251 glioma cells inhibited the expression of P-Akt. Taken together, these findings suggest that the EGFR/Akt signaling pathway involved in the regulation of U251 glioma cells proliferation and migration. It’s mechanism is possible that after the EGFR/Akt signaling pathway activated, caused the high expression of downstream proteins.

Keywords

glioma, epidermal growth factor, proliferation, migration

References

  1. 1. Van Meir, E.G., et al., Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin, 2010. 60(3): p. 166-93.
  2. 2. Louis, D.N., et al., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007. 114(2): p. 97-109.
  3. 3. Wiedemeyer, R., et al., Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell, 2008. 13(4): p. 355-64.
  4. 4. Coras, R., et al., The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther, 2007. 6(6): p. 1745-54.
  5. 5. Wu, Z., et al., Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate, 2013. 73(6): p. 596-604.
  6. 6. Li, J.C., et al., Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma. Tumour Biol, 2014. 35(1): p. 651-7.
  7. 7. Jia, J., et al., The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. Clin Transl Oncol, 2016. 18(6): p. 592-8.
  8. 8. Mu, L., et al., beta-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway. Int J Oncol, 2016. 49(4): p. 1427-36.
  9. 9. Ohashi, S., et al., Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology, 2015. 149(7): p. 1700-15.
  10. 10. Bonaccorsi, L., et al., Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol, 2004. 130(10): p. 604-14.
  11. 11. P, O.c., et al., The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol, 2002. 38(7): p. 627-40.
  12. 12. Ellerbroek, S.M., et al., Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res, 2001. 61(5): p. 1855-61.
  13. 13. Yufen, X., et al., The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus, 2016. 5(1): p. 016-2873.
  14. 14. Normanno, N., et al., Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006. 366(1): p. 2-16.
  15. 15. Walbert, T. and K. Chasteen, Palliative and supportive care for glioma patients. Cancer Treat Res, 2015. 163: p. 171-84.
  16. 16. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, 2015. 65(1): p. 5-29.
  17. 17. Mellinghoff, I.K., et al., Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med, 2005. 353(19): p. 2012-24.
  18. 18. Chakravarti, A., A. Dicker, and M. Mehta, The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys, 2004. 58(3): p. 927-31.
  19. 19. Nishikawa, R., et al., A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A, 1994. 91(16): p. 7727-31.
  20. 20. Szerlip, N.J., et al., Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A, 2012. 109(8): p. 3041-6.
  21. 21. Zhang, H., et al., ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest, 2007. 117(8): p. 2051-8.
  22. 22. Huang, P.H., A.M. Xu, and F.M. White, Oncogenic EGFR signaling networks in glioma. Sci Signal, 2009. 2(87).
  23. 23. Li, X., et al., PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget, 2016. 7(22): p. 33440-50.

Cite this Article:

  • BibTex
  • RIS
  • APA
  • Harvard
  • IEEE
  • MLA
  • Vancouver
  • Chicago

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue November 2019

Volume 8, November 2019


Table of Contents


Order Print Copy

World-wide Delivery is FREE

Share this Issue with Friends:


Submit your Paper